ANZCTR search results

Phase 3 This study is comparing the effectiveness of the drugs tamoxifen versus anastrozole in postmenopausal women with hormone sensitive ductal carcinoma in situ (DCIS). This is an ANZ 02P2/ International Breast Cancer Intervention Study: IBIS-II DCIS. Who is it for? You can join this trial if: You are a postmenopausal woman aged between 40 and 70 years. You must have had DCIS diagnosed in one breast within the last 6 months. The DCIS must have been hormone sensitive and have been locally removed (i.e.not by mastectomy). Trial details Participants will be randomly divided into two groups. One group receives tamoxifen plus a non-active compound in place of anastrozole. The other group receives anastrozole plus a non-active compound in place of tamoxifen. These are taken orally, every day for 5 years. The study aims to compare how effective the two drugs are in preventing and controlling locally any subsequent disease, in the same or the other breast. DCIS has the potential to develop into breast cancer which can spread to other places in the body. Both tamoxifen and anastrozole lower levels of the hormone oestrogen in the body and are used in women already diagnosed with breast cancer. Tamoxifen is used in some women with DCIS for the prevention of breast cancer. This trial is looking at whether anastrozole is as effective as tamoxifen in preventing further DCIS and breast cancer.

Randomised Conrolled Trial looking at effectiveness of 6 weeks of daily 30-minute stretch intervention on hamstring muscle extensibility in able-bodied population

Improved participation in screening for bowel cancer is desirable. Currently population scale bowel cancer screening program delivery is by mailed offer from a central screening service and invitations include a faecal occult blood detection kit. Invitees may decline the offer because they do not feel they are at risk, or because they do not engage with the program. We have developed invitation letters to that include either improved risk messages or messages from previous screening participants in order to overcome these barriers. We will randomly select invitees from the electoral roll and compare population screening participation between groups with or without the preliminary letter to determine which program results in the greater participation rate. Improved participation in screening will ultimately reduce deaths from bowel cancer

The aim of this project is to test the immediate and long-term effects of a nursing intervention on improving pain of older patients in the hospital setting. A controlled trial will be undertaken in the geriatric evaluation and management units of two metropolitan hospitals. An organisational improvement model underpins the intervention, which comprises an educational program and clinical role modelling. This model considers the complexity of pain management activities in multidimensional ways.

A pilot study to investigate the safety of using local anaesthetic eye drops to control pain following minor corneal injuries.

The University of Adelaide, with funding from the Australian Government, Department of Health and Ageing (DoHA) is currently conducting a large research Trial investigating and evaluating the clinical effectiveness, cost effectiveness and safety of point of care testing (PoCT) in general practice. The Trial is of considerable national significance. In 2002, DoHA commissioned a review for the Medical Services Advisory Committee (MSAC) on the role and value of point of care testing in Australia. This report highlighted the potential advantages of PoCT, particularly in rural and remote practices, but concluded that further evidence needed to be collected concerning the clinical and economic benefits as well as the analytical performance of PoCT in the community setting. The Point of Care Testing Trial will occur in three settings: urban, rural and remote. It will aim to demonstrate whether or not local pathology testing will improve and create more efficient care and be acceptable to both general practitioners (GPs) and their patients. It will also test whether these innovative models can be sustainable and safely implemented in general practice. Approximately 6,000 patients of 60 general practices will participate in this Trial. Patients from half the practices will participate fully in the Trial and have their pathology tests conducted at the GP`s surgery; these will be known as the intervention group, while the other half will act as the control group and have their pathology testing done by the usual pathology group selected by their surgery. Patients eligible to participate in the Trial are those 18 years and over and who have established diabetes, cardiovascular disease or who are taking anticoagulant medicine such as Warfarin. There will be four tests used for the Trial. These four tests are: Haemoglobin A1c (HbA1c): a blood test for monitoring the control of diabetes in patients with established diabetes. Urine Albumin:Creatinine ratio (ACR): a urine test for detecting and, in this Trial, monitoring microalbuminuria (early renal disease) in patients with established diabetes. Lipids: a blood test that measures different blood fats (total cholesterol [TC], high density lipoprotein [HDL] cholesterol, and triglyceride [TGL] in patients in this Trial who have hyperlipidaemia and who are taking lipid lowering drugs. International Normalised Ratio (INR): a blood test that measures clotting time in patients receiving oral anticoagulant therapy (such as Warfarin). Three different testing devices will be used in this Trial. These are the DCA 2000 (HbA1c and urine ACR [micralbuminuria]); the Cholestech LDX (blood lipids); and the CoagChek S (INR). All devices and consumables will be supplied to practices for the life of the Trial.